Research across Cancer
Related studies from across the Cancer family.
SABR Protocol Deviations Linked to Poorer Survival in Oligometastatic Head and Neck Cancer
Major protocol deviations cut survival time for head and neck cancer patients
This exploratory analysis of a randomized phase 2 trial (GORTEC 2014-04) in 69 patients with oligometastatic head and neck cancer found that…
Strict radiation quality checks linked to better survival for head and neck cancer patients. Minor or major errors during treatment reduced …
Salvage radiotherapy for limited metastatic relapse in small cell lung cancer after durvalumab
Two patients with limited-stage small cell lung cancer had durable disease control after salvage radiotherapy and immunotherapy
This case report describes two patients with limited-stage small cell lung cancer who developed limited metastatic relapse after chemoradiot…
Two limited-stage small cell lung cancer patients stayed stable for over four years after targeted radiation and continued immunotherapy.
Curative-intent local therapy linked to improved survival in isolated contralateral axillary breast metastasis
Local therapy linked to better survival in advanced breast cancer patients with specific metastases
This retrospective cohort study of 1110 patients across two tertiary centers compared outcomes in isolated contralateral axillary metastasis…
Patients with specific breast cancer spread to the opposite armpit survived longer when receiving surgery or radiation compared to systemic …
Lu-PSMA-617 reduces disease progression versus deferred ADT in oligometastatic HSPC in phase 2 trial
Can a targeted radiation drug delay prostate cancer progression without hormone therapy?
A phase 2 randomized controlled trial of 58 men with biochemically recurrent oligometastatic hormone-sensitive prostate cancer found Lu-PSMA…
A targeted radiation drug delayed prostate cancer progression by 20 months in early-stage patients without requiring hormone therapy first.
Phase 3 Study of Lutetium (177Lu) Vipivotide Tetraxetan in OMPC Patients
Can a new treatment delay prostate cancer from spreading further?
Phase 3 trial evaluates lutetium (177Lu) vipivotide tetraxetan for oligometastatic prostate cancer. Primary outcome: Metastasis Free Surviva…
A new prostate cancer treatment aims to delay cancer spread and spare men from intensive hormone therapy while preserving their quality of l…